A Nanocrystal-Based Device for Point-of-Care Molecular Differential Diagnostics

描述(申请人提供)：这项第一阶段申请的具体目标是使用核酸修饰的纳米探针来开发一种新的、负担得起的核酸检测系统，用于快速识别传染病。近年来，使用核酸技术(NAT)的体外诊断的应用和市场稳步增长。核酸检测几乎应用于生物样本检测的所有领域，包括基因分型、传染病诊断、癌症和心脏标记物检测，以及工业和环境测试。然而，许多基于NAT的测试都是在具有高度自动化系统的集中位置执行的，而不是像医生预期的那样作为医疗保健点诊断格式执行。将样本运送到中央检测实验室所需的时间和成本延迟了结果和患者的及时治疗。本申请描述了使用肽核酸修饰的量子点纳米探针来快速和灵敏地检测多重PCR产物。这一新方法消除了对荧光探测器或扫描仪等昂贵检测设备的需要，大大降低了该过程的资本和测试成本。此外，Lynntech将把这项技术与我们的联盟合作伙伴提供的强大的多路放大技术结合在一起。由此产生的产品是一种真正的现场或现场可部署的诊断分析，允许以极大的降低成本进行快速和高通量测试。这一创新方法将使人们能够快速识别传染病(例如禽流感或SARS)和其他病原微生物。这项应用的具体目的是提供一种快速且廉价的设备，用于检测和识别传染病。这项技术将大大降低测试成本和测试时间，1小时内返回阳性或阴性结果。这项技术可用于检测新出现的威胁，如禽流感和SARS或更常见的病原微生物。

DESCRIPTION (provided by applicant): The specific aim of this Phase I application is to use nucleic acid modified nanoprobes for the development of a new and affordable nucleic acid detection system for the rapid identification of infectious diseases. The applications and market of in vitro diagnostics using nucleic acid technologies (NAT) has grown steadily over the recent years. Nucleic acid testing is being applied to practically all areas of biological sample testing including genotyping, infectious-disease diagnostics, cancer and cardiac marker testing, and industrial and environmental tests. However, instead of being performed as a point-of-care diagnostic format as physicians have anticipated, many of these NAT based tests are being carried out at a centralized location with highly automated systems. The time and cost required for shipping samples to centralized testing labs delays results and timely treatment of patients. This application describes the use of peptide nucleic acid modified quantum dot nanoprobes for rapid and sensitive detection of multiplex PCR products. This new approach eliminates the need for expensive detection equipment such as fluorescent detectors or scanners, greatly reducing the capital and testing cost of the process. In addition, Lynntech will couple this technology with a powerful, multiplex amplification technology from our alliance partner. The resulting product is a truly on-site or field-deployable diagnostic assay allowing rapid and high-throughput testing at a greatly reduced cost. This innovative approach will enable rapid identification of infectious diseases (e.g., avian flu or SARS) and other pathogenic microorganisms. The specific aim of this application is to provide a rapid and inexpensive device for detection and identification of infectious diseases. This technology will significantly reduce testing cost and testing time with a positive or negative result returned in 1 hour. This technology can be applied for detection of emerging threats such as the avian flu and SARS or more common pathogenic microorganisms.